Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus

References

• ReddehaseMJAntigens and immunoevasins: opponents in cytomegalovirus immune surveillanceNat Rev Immunol200221183184412415307
   PubMed Web of Science ®Google Scholar
• BateSLDollardSCCannonMJCytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004Clin Infect Dis201050111439144720426575
   PubMed Web of Science ®Google Scholar
• BeamERazonableRRCytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatmentCurr Infect Dis Rep201214663364122992839
   PubMed Web of Science ®Google Scholar
• Torre-CisnerosJToward the individualization of cytomegalovirus control after solid-organ transplantation: the importance of the “individual pathogenic balance”Clin Infect Dis20094981167116819751150
   PubMed Web of Science ®Google Scholar
• HumarALebranchuYVincentiFThe efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipientsAm J Transplant20101051228123720353469
   PubMed Web of Science ®Google Scholar
• PayaCHumarADominguezEEfficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipientsAm J Transplant20044461162015023154
   PubMed Web of Science ®Google Scholar
• EinseleHHebartHKauffmann-SchneiderCRisk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infectionBone Marrow Transplant200025775776310745262
   PubMed Web of Science ®Google Scholar
• ManuelOPangXLHumarAKumarDDoucetteKPreiksaitisJKAn assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variantsJ Infect Dis2009199111621162819385736
   PubMed Web of Science ®Google Scholar
• RazonableRREpidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipientsAm J Health Syst Pharm2005628 Suppl 1S7S1315821266
   PubMed Web of Science ®Google Scholar
• Le PageAKJagerMMIwasenkoJMScottGMAlainSRawlinsonWDClinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipientsClin Infect Dis20135671018102923243176
   PubMed Web of Science ®Google Scholar
• LurainNSChouSAntiviral drug resistance of human cytomegalovirusClin Microbiol Rev201023468971220930070
   PubMed Web of Science ®Google Scholar
• BognerEHuman cytomegalovirus terminase as a target for antiviral chemotherapyRev Med Virol200212211512711921307
   PubMed Web of Science ®Google Scholar
• BuergerIReefschlaegerJBenderWA novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene productsJ Virol200175199077908611533171
   PubMed Web of Science ®Google Scholar
• BognerERadsakKStinskiMFThe gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activityJ Virol1998723225922649499084
   PubMed Web of Science ®Google Scholar
• HwangJSBognerEATPase activity of the terminase subunit pUL56 of human cytomegalovirusJ Biol Chem200227796943694811744697
   PubMed Web of Science ®Google Scholar
• PilorgeLBurrelSAit-ArkoubZAgutHBoutolleauDHuman cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphismAntiviral Res201411181225194992
   PubMed Web of Science ®Google Scholar
• GriffithsPDEmeryVCTaming the transplantation troll by targeting terminaseN Engl J Med2014370191844184624806164
   PubMed Web of Science ®Google Scholar
• GableJEAckerTMCraikCSCurrent and potential treatments for ubiquitous but neglected herpesvirus infectionsChem Rev1022014 Epub ahead of print
   Web of Science ®Google Scholar
• BognerEReschkeMReisBMockenhauptTRadsakKIdentification of the gene product encoded by ORF UL56 of the human cytomegalovirus genomeVirology199319612902938395117
   PubMed Web of Science ®Google Scholar
• ChampierGCouvreuxAHantzSPutative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activityAntiviral Ther2008135643654
   PubMed Web of Science ®Google Scholar
• CouvreuxAHantzSMarquantRInsight into the structure of the pUL89 C-terminal domain of the human cytomegalovirus terminase complexProteins20107861520153020099308
   PubMed Web of Science ®Google Scholar
• ScheffczikHSavvaCGHolzenburgAKolesnikovaLBognerEThe terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structureNucleic Acids Res20023071695170311917032
   PubMed Web of Science ®Google Scholar
• GiesenKRadsakKBognerEThe potential terminase subunit of human cytomegalovirus, pUL56, is translocated into the nucleus by its own nuclear localization signal and interacts with importin alphaJ Gen Virol200081Pt 92231224410950981
   PubMed Web of Science ®Google Scholar
• AdamSAGeraceLCytosolic proteins that specifically bind nuclear location signals are receptors for nuclear importCell19916658378471653647
   PubMed Web of Science ®Google Scholar
• WeisKDingwallCLamondAICharacterization of the nuclear protein import mechanism using Ran mutants with altered nucleotide binding specificitiesEMBO J19961524712071289003787
   PubMed Web of Science ®Google Scholar
• MelchiorFPaschalBEvansJGeraceLInhibition of nuclear protein import by nonhydrolyzable analogues of GTP and identification of the small GTPase Ran/TC4 as an essential transport factorJ Cell Biol19931236 Pt 2164916598276887
   PubMed Web of Science ®Google Scholar
• ThomaCBorstEMesserleMRiegerMHwangJSBognerEIdentification of the interaction domain of the small terminase subunit pUL89 with the large subunit pUL56 of human cytomegalovirusBiochemistry200645298855886316846228
   PubMed Web of Science ®Google Scholar
• NadalMMasPJBlancoAGStructure and inhibition of herpesvirus DNA packaging terminase nuclease domainProc Natl Acad Sci U S A201010737160781608320805464
   PubMed Web of Science ®Google Scholar
• ChampierGHantzSCouvreuxANew functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDcAntiviral Ther2007122217232
   Web of Science ®Google Scholar
• DittmerADrachJCTownsendLBFischerABognerEInteraction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosidesJ Virol20057923146601466716282466
   PubMed Web of Science ®Google Scholar
• ScholzBRechterSDrachJCTownsendLBBognerEIdentification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirusNucleic Acids Res20033151426143312595550
   PubMed Web of Science ®Google Scholar
• BorstEMKleine-AlbersJGabaevIThe human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89J Virol20138731720173223175377
   PubMed Web of Science ®Google Scholar
• McVoyMANixonDEImpact of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturationJ Virol20057917111151112716103162
   PubMed Web of Science ®Google Scholar
• KroskyPMUnderwoodMRTurkSRResistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56J Virol1998726472147289573236
   PubMed Web of Science ®Google Scholar
• UnderwoodMRHarveyRJStanatSCInhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene productJ Virol19987217177259420278
   PubMed Web of Science ®Google Scholar
• KomazinGTownsendLBDrachJCRole of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosidesJ Virol200478271071514694102
   PubMed Web of Science ®Google Scholar
• ReefschlaegerJBenderWHallenbergerSNovel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of actionJ Antimicrob Chemother200148675776711733458
   PubMed Web of Science ®Google Scholar
• LischkaPHewlettGWunbergTIn vitro and in vivo activities of the novel anticytomegalovirus compound AIC246Antimicrob Agents Chemother20105431290129720047911
   PubMed Web of Science ®Google Scholar
• LischkaPZimmermannHAntiviral strategies to combat cytomegalovirus infections in transplant recipientsCurr Opin Pharmacol20088554154818662804
   PubMed Web of Science ®Google Scholar
• StoelbenSArnsWRendersLPreemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a studyTranspl Int2014271778624164420
   PubMed Web of Science ®Google Scholar
• KaulDRStoelbenSCoberEFirst report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246Am J Transplant20111151079108421521474
   PubMed Web of Science ®Google Scholar
• ChemalyRFUllmannAJStoelbenSLetermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantationN Engl J Med2014370191781178924806159
   PubMed Web of Science ®Google Scholar
• MarschallMStammingerTUrbanAIn vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic virusesAntimicrob Agents Chemother20125621135113722106211
   PubMed Web of Science ®Google Scholar
• GoldnerTHewlettGEttischerNRuebsamen-SchaeffHZimmermannHLischkaPThe novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminaseJ Virol20118520108841089321752907
   PubMed Web of Science ®Google Scholar
• GoldnerTZimmermannHLischkaPPhenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovirAntiviral Res2015116c485025637709
   PubMed Web of Science ®Google Scholar
• GoldnerTHempelCRuebsamen-SchaeffHZimmermannHLischkaPGeno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposureAntimicrob Agents Chemother201458161061324189264
   PubMed Web of Science ®Google Scholar
• KropeitDPhase I safety and PK data of the novel anti-HCMV terminase inhibitor AIC246Abstract 1994 presented at the 50th Interscience Conference of Antimicrobial Agents and ChemotherapyBoston, MA, USASeptember 12–15, 2010
   Google Scholar
• MccormickDAIC246 does not exhibit clinically significant drug-drug interactions when administered with immunosuppressive drugs in transplant recipientPaper presented at: 51th Interscience Conference of Antimicrobial Agents and ChemotherapyChicago, IL, USASeptember 17–20 2011
   Google Scholar